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Conventional chemotherapeutics target the proliferating fraction of cells in the patient’s
body, which will include the tumor cells, but are also toxic to actively proliferating normal
tissues. Cellular stresses, such as those imposed by chemotherapeutic drugs, induce cell
cycle checkpoint arrest, and currently approaches targeting these checkpoints are being
explored to increase the efﬁcacy and selectivity of conventional chemotherapeutic treat-
ments. Loss of a checkpoint may also make cancer cells more reliant on other mechanisms
to compensate for the loss of this function, and these compensatory mechanisms may
be targeted using synthetic lethal approaches. Here we will discuss the utility of targeting
checkpoint defects as novel anti-cancer therapies.
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THE CELL CYCLE AS AN ANTI-CANCER TARGET
Conventional chemotherapeutic agents continue to have wide-
spread application in the treatment of a wide range of cancers.
However, the obvious drawback of these agents, the normal tis-
sue toxicity and their lack of activity in certain tumor types,
is driving the development of more selective drugs that target
cancer-speciﬁc defects. The success of such targeted agents as Her-
ceptin in ErbB2 over expressing breast cancers (Esteva et al., 2010),
Gleevec/Imatinib in BCR–Abl dependent CML (Druker, 2002),
and Kit positive GIST (Sleijfer et al., 2008), and recently the BRaf
inhibitors in melanoma (Bollag et al., 2010), has demonstrated
the effectiveness of such an approach. One mechanism that is of
increasing interest as an anti-cancer target is the cell cycle, specif-
ically the cell cycle checkpoints which are commonly defective
in cancers. Much of the current research employs these defects
to increase the efﬁcacy of conventional chemotherapeutics. Here
we present ideas for targeting other checkpoint defects without
the use of conventional chemotherapeutics, instead relying on cell
damage that accumulates in absence of normal checkpoint con-
trols to provide stress, that when correctly targeted, drives tumor
cell speciﬁc cytotoxicity.
One of the hallmarks of cancer is uncontrolled proliferation, a
consequence of loss of normal cell cycle control, which underlies
tumor growth (Hanahan and Weinberg, 2011). The high prolif-
erative index of cancers compared to their surrounding normal
tissuewas recognized very early as common feature of cancers. The
higher proliferation rate of cancer cells has been used to provide
a degree of targeting for conventional chemotherapeutic drugs,
which preferentially kill rapidly proliferating cells. This targeting
of the proliferative fractionof cells in patients is also the basis of the
normal tissue toxicities commonly associated with conventional
chemotherapeutics, with the drugs destroying normally prolifer-
ating tissues in the body, such as the hematopoietic system and
intestinal epithelial lining, thereby limiting their clinical utility.
More recently, normal cell cycle regulators, particularly the cyclin
dependent kinases (cdks), a family of protein kinases controlling
cell cycle progression, have been investigated as anti-cancer tar-
gets. Cdks are protein kinase subunits that form a complex with
a regulatory cyclin protein, and it is the various isoforms of
these cyclin/cdk complexes that regulate the ordered progression
through the cell cycle (Malumbres and Barbacid, 2009). Like con-
ventional chemotherapeutic agents, cdk directed drugs also target
the proliferating fraction of cells in the body, but without the
genotoxicity associated with chemotherapeutics. The cdk directed
drugs are generally well tolerated with acceptable normal tissue
toxicity proﬁles, but this approach hasmeet with onlymodest suc-
cess in terms of their anti-cancer activity (Lapenna and Giordano,
2009).
Recently, attention has focused on the cell cycle mechanisms
known as checkpoints. These respond to internal stresses such as
incomplete replication and external stresses such as DNA damag-
ing agents to block cell cycle progression until the stress is resolved
or repaired (Medema and Macurek, 2011). Checkpoints respond
to speciﬁc forms of stress to impose an arrest at speciﬁc points in
the cell cycle. For example,DNAdamageduringG1phase and anti-
proliferative signals induce a G1 phase arrest prior to entry into
S phase. Damage during S phase or stresses that affect replication
forks and slow S phase progression cause an S phase checkpoint,
whereas DNA damage during G2 phase or failure to completely
decatenate the chromosomes can trigger a G2 phase arrest, block-
ing entry into mitosis. Finally, defects that threaten the ﬁdelity of
partitioning of the replicated genome, normally a consequence of
failure of proper mitotic spindle function, block exit from mitosis
(Figure 1). Thus checkpoints function in normal cell cycle pro-
gression to ensure the ﬁdelity and completion of each phase of
the cell cycle before progression to the subsequent phase, and in
response to external stresses, to produce two genetically identi-
cal daughter cells. Many conventional chemotherapeutic agents
are genotoxins and thus initiate cell cycle checkpoint responses
in both normal tissue and cancer cells. For example, ionizing
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radiation causes double stranded DNA breaks which can trigger
G1 and G2 phase checkpoint arrests, and anti-metabolites such
as hydroxyurea and 5-FU block replication triggering an S phase
arrest. Genotoxins such as alkylating agents or TopoII inhibitors
can trigger G2 phase checkpoints, while anti-microtubule drugs
trigger the mitotic checkpoint (Figure 1). Thus the presence of
functional checkpoint responses in cancer cells is likely to reduce
the efﬁcacy of these drugs through the normal checkpoint role of
blocking cell cycle progression and facilitating repair of the drug-
induced damage (Kuntz and O’Connell, 2009; Ma et al., 2011;
Medema and Macurek, 2011).
Each checkpoint arrest utilizes different mechanisms that sense
the stress or damage inﬂicted and impose the cell cycle arrest.
Checkpoint mechanisms are commonly divided into two cate-
gories, p53-dependent and p53-independent mechanisms. P53 is
rapidly stabilized in response to a range of genotoxic insults, and
the increased levels of p53 are responsible for cell cycle arrests in
G1 and G2 phases in cell lines in vitro, and for signaling apop-
tosis in response to excessive or persistent damage. This latter
function may be its primary role in vivo (Jackson et al., 2011).
Thus the frequent loss of p53 in cancers is most likely to enhance
their ability to survive in the face of high levels of damage/stress.
Another consequence of p53 loss is that the checkpoint response to
damage is now entirely reliant on p53-independent mechanisms.
These are commonly regulated through the upstream checkpoint
kinases ataxia telangiectasia mutated (ATM) and ataxia telangiec-
tasia and Rad3 related (ATR) which in turn regulate the activity
of the checkpoint kinases Chk1 and Chk2. The mitotic check-
point utilizes a different set of genes to detect spindle defects,
many localized to kinetochores, including the Mad and Bub gene
families andAurora kinases (Figure 2). Checkpoint signaling com-
ponents also have roles in regulating repairmechanisms (Sorensen
et al., 2005; Auclair et al., 2009; Gohler et al., 2011), thus con-
tributing to both the arrest and repair of damage triggering the
arrest.
DEFECTIVE CHECKPOINT CONTROL IN CANCER
Many tumor suppressors are components of cell cycle check-
points, e.g., p53, ATM, p16CDKN2A, and BRCA1, which function
in checkpoint responses to a range of different stresses (Pavey
et al., 1999; McDonald and El-Deiry, 2001; Stewart et al., 2003;
Medema and Macurek, 2011). The frequency of tumor suppres-
sor loss indicates that checkpoint defects are a common feature of
cancers. The loss of checkpoint controls provides obvious growth
advantages to cancer cells in that they are less sensitive to the
normal growth signals that regulate normal cell proliferation.
For example, cells defective for the p16–Rb G1 phase check-
point are insensitive to a range of negative proliferative signals
(Giacinti and Giordano, 2006). In addition, loss of checkpoint
controls also increases genomic instability, another hallmark of
cancer, which can provide cancer cells with an evolutionary or
adaptive advantage, allowing them to modify their transcriptome
FIGURE 2 | Checkpoint regulators.
FIGURE 1 | Cell cycle checkpoints.
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and/or genome to increase their ability to thrive in new tissue
environments (Hanahan and Weinberg, 2011). However, a neces-
sary corollary of this is that because checkpoints normally have
a protective role, allowing cells to repair any stress or damage
before progressing in the cell cycle, defects in checkpoints must
increase the burden of endogenous damage in the cancer cells.
Despite this, cancer cells survive and thrive with this increased
stress load (Halazonetis et al., 2008). The elevated stress levels
may be a driver of the higher level of apoptosis often found in
tumors compared to normal tissue. This elevated stress must be
accommodated by the cells utilizing either; (1) a novel mechanism
to cope with the stress, (2) an adaptation to accommodate the
stress, or (3) becoming more reliant on alternative stress response
mechanisms. All of these mechanisms are equally likely and it
may be that cancer cells utilize a combination of all three. What-
ever the mechanism, cancer cells now offer a point of divergence
from normal tissue in that they are checkpoint defective and thus
more reliant on alternative mechanisms to cope with a stress.
The increased reliance on alternative stress response mechanisms
would predict that if it is possible to disable these mechanisms,
this should selectively reduce the viability of the cancer cells
with normal tissue being protected by their intact checkpoint
response.
EXPLOITING CHECKPOINT DEFECTS AS ANTI-CANCER
TARGETS
TARGETING p53
The loss of checkpoint function is currently being exploited in
preclinical models of p53 mutant tumors. Loss of p53 results in
cells being reliant on the G2 phase ATM/ATR–Chk1/2 dependent
checkpoint in responses to genotoxic chemotherapeutic drugs
such as topoisomerase inhibitors and anti-metabolites. This check-
point is readily bypassed using Chk1 inhibitors, resulting in cells
undergoing an aberrant mitosis and eventually an increase in cell
death (Mukhopadhyay et al., 2005; Dai and Grant, 2010; Morgan
et al., 2010; Ma et al., 2011). The shortcoming of this approach
is its continued reliance on conventional chemotherapeutic drugs
with their associated normal tissue toxicities, although this may
be attenuated to some extent by the reduced dose of chemother-
apeutic agent required when used in combination with the Chk1
inhibitor. Doses of a range of chemotherapeutic agents can be
reduced at least twofold to achieve better anti-tumor activity when
combined with a range of Chk1 inhibitors in xenograft mod-
els. Combination of Chk1 inhibitors with docetaxel decreased
tumor volumes a further 30–50% compared with docetaxel alone
(Zhang et al., 2009), and increased anti-tumor activity by up to
fourfold in combination with gemcitabine (Blasina et al., 2008;
Guzi et al., 2011), and up to twofold with camptothecin (Tse
et al., 2007). Chk1 inhibitors also increased the anti-tumor activ-
ity of suboptimal doses of gemcitabine and irinotecan by over
fourfold (Zabludoff et al., 2008; reviewed in Garrett and Collins,
2011). Although the loss of normal p53 function may also reduce
the sensitivity of cells to pro-apoptotic stimuli, this approach
provides proof of principle that targeting defective checkpoints
can provide tumor selective cytotoxicity in a genetically (p53
mutant) or functionally (checkpoint defective) deﬁned subset of
cancers.
SYNTHETIC LETHAL TARGETING OF DEFECTIVE CHECKPOINTS
The inhibition of Chk1 in p53 mutant cancers is an example of
Synthetic Lethality. This is where loss of a stress response mech-
anism results in reduced cell viability that is tolerated by the
cancer, but when combined with the loss of the compensatory
mechanism results in complete loss of viability (Kaelin, 2005;
Figure 3). Targeting the compensatory mechanisms to inhibit its
function renders the cancer cell incapable of coping with the spe-
ciﬁc stress resulting in a dramatic loss of viability. In the case
of Chk1 inhibition, the selectivity is provided by the loss of p53
function and application of an externally applied genotoxic stress
FIGURE 3 |The stress responses are functional in normal tissue (A),
and loss of a stress response will reduce cell viability in the face of
that stress and the cell become reliant on a secondary mechanism to
adapt to the stress (B), whereas loss of primary response and the
adaptation result in complete loss of viability (C).The loss of the
secondary adaptation is known as synthetic lethality.
FIGURE 4 | Administration of genotoxic drugs can be readily
responded to by p53-dependent mechanisms in normal tissues (A),
whereas loss of p53 function will reduce cell viability and result in
cells becoming reliant on the Chk1 dependent G2 phase checkpoint
(B). Inhibition of Chk1 in combination with drug treatment results in loss of
viability (C). The same scenario operates with BRCA2 mutant cells where
PARP inhibition blocks BER to produce synthetic lethality in response to
endogenous DNA damage.
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(Figure 4). Synthetic lethality is exempliﬁed in BRCA2 mutant
breast cancer cells where base excision repair (BER) compensates
for the loss of homologous recombination repair, a consequence
of BRCA2 loss of function. Inhibiting BER using PARP inhibitors
results in selective cytotoxicity of the BRCA2 mutant breast can-
cers, while normal tissue is protected due to the intact BRCA2
homologous recombination pathway (Farmer et al., 2005; Ash-
worth, 2008). In this case, the stress is an endogenous stress in
the form of normally occurring DNA damage. This has the ben-
eﬁt of an even better toxicity proﬁle, as no genotoxic agents are
required to produce the synthetic lethality, reducing the potential
for normal tissue toxicities associated with the genotoxin admin-
istration. Another example of synthetic lethality is the mecha-
nism by which histone deacetylase inhibitors (HDACi) kill cells
that are defective for a G2 phase cell cycle checkpoint triggered
by HDACi. We have previously demonstrated that loss of this
HDACi-sensitive checkpoint response resulted in rapid apopto-
sis following HDACi treatment (Qiu et al., 2000; Krauer et al.,
2004). In this case, failure to checkpoint arrest results in cells
undergoing an aberrant mitosis (Qiu et al., 2000; Cimini et al.,
2003; Warrener et al., 2003), which should be detected by the
mitotic spindle assembly checkpoint and arrest cells in mitosis
until the defect is repaired (Rieder and Maiato, 2004). However,
HDACi treatment rapidly overcomes this checkpoint response
resulting in mitotic slippage (Warrener et al., 2003; Dowling et al.,
2005; Stevens et al., 2008), and it is this slippage that triggers the
apoptosis observed (Weaver and Cleveland, 2005). Thus, loss of a
checkpoint control may be used as a target to selectively destroy
tumors harboring that checkpoint defect. The efﬁcacy of PARP
inhibitors in BRCA2 mutant cancers and our work with HDACi
and Chk1 inhibitors, demonstrate that targeting a defective check-
point and disrupting the compensatory mechanisms can deliver
tumor selective cytotoxicity by synthetic lethality. In the case of
the PARP inhibitors and HDACi, the stresses that trigger the cell
death observed are endogenous damage, obviating the require-
ment for an externally applied stressor as is required for the Chk1
inhibition in p53 mutant tumors. The reliance on endogenous
stress increases the selectivity of treatment and thereby reduces
the potential normal tissue toxicities. The success of this approach
has resulted in an increasing number of synthetic lethality screens
being performed that have identiﬁed novel drugs or targets for
speciﬁc tumor types (Azorsa et al., 2009; Kaelin, 2009; Scholl
et al., 2009; Astsaturov et al., 2010; Kim et al., 2010; Kuiken and
Beijersbergen, 2010; Potratz et al., 2010; Martin et al., 2011). A
majority of these have used siRNA libraries to identify compo-
nents of the compensatory mechanism in a speciﬁc genetic or
mutant pathway background.We propose that a similar approach
could be used to identify synthetic lethal combinationswith check-
point defects as a functional rather than speciﬁc genetic defect.
As with all targeted therapeutics, it would also be necessary to
identify a molecular signature for the defective checkpoint. Our
own experience from in vitro studies would suggest that targeting
defective G2 phase checkpoint controls might be a more effective
strategy as the consequence of a defective G2 phase checkpoint
is generally cells undergoing an aberrant mitosis, the outcome
of both HDACi treatment and bypassing the ATM/ATR–Chk1
dependent G2 phase checkpoint (Gabrielli et al., 2007; Stevens
et al., 2008; Dai and Grant, 2010; Ma et al., 2011). Aberrant
mitosis is associated with triggering of the mitotic spindle assem-
bly checkpoint which blocks cells in mitosis until the ﬁdelity
of partitioning of the replicated chromosomes can be assured.
Activation of the spindle assembly checkpoint also appears to
sensitize cells to pro-apoptotic signals generated when mitosis
fails (Castedo et al., 2004; Rieder and Maiato, 2004; Sudo et al.,
2004; Gabrielli et al., 2007), making this a desirable outcome for
a chemotherapeutic treatment. The success of anti-mitotic drugs
is strong evidence that utilizing the spindle assembly checkpoint
as a source of apoptotic stimulus is effective (Weaver and Cleve-
land, 2005; Gascoigne and Taylor, 2009; Kaestner and Bastians,
2010).
In summary, defective checkpoints offer a relatively untapped
area of potentially selective cytotoxic therapies for a range of can-
cers. They offer selectivity byway of the defective checkpoint being
an intrinsic property of the cancer, while the normal tissue is
protected by their intact checkpoints, and tumor cell cytotoxic-
ity from the loss of a protective mechanism. The challenges that
lie ahead are to identify means of targeting the defective check-
points and identifying signatures of the defects, so that patients
with checkpoint defective tumors that would respond to these
selective therapeutic approaches can be identiﬁed.
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